Marker awarded $2.6M FDA Orphan Products grant to fund MT-601 pancreatic cancer Phase 1

Marker awarded a $2.6 million FDA Orphan Products Clinical Trials grant to support a Phase 1 study of MT-601 in locally advanced unresectable pancreatic cancer.Key Highlights:Original SEC Filing: Marker Therapeutics, Inc. [ MRKR ] - 8-K - Oct. 19, 2026This is an AI-powered summary. It may contain i…